Molecular Monitoring in Acute Myeloid Leukemia Patients Undergoing Matched Unrelated Donor – Hematopoietic Stem Cell Transplantation: Single Center Experience

1. Loke J, Malladi R, Moss P, Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020;188(1):129-146. doi:10.1111/bjh.1635510.1111/bjh.16355697249231823351Search in Google Scholar

2. Horowitz, M., Schreiber, H., Elder, A. et al. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant 53, 1379–1389 (2018). https://doi.org/10.1038/s41409-018-0171-z10.1038/s41409-018-0171-z628270129670211Search in Google Scholar

3. Schuurhuis GJ, Heuser M, Freeman S, at el. Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. Blood. 2018; 131(12): 1275–91. https://doi.org/10.1182/blood-2017-09-80149810.1182/blood-2017-09-801498586523129330221Search in Google Scholar

4. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4): 424–447. doi:10.1182/blood-2016-08-73319610.1182/blood-2016-08-733196529196527895058Search in Google Scholar

5. Khanal, Nabin & Banskota, Shristi & Bhatt, Vijaya. (2020). Novel treatment paradigms in acute myeloid leukemia. Clinical Pharmacology & Therapeutics. 10.1002/cpt.1962.10.1002/cpt.196232572947Search in Google Scholar

6. Dillon R, Hills R, Freeman S, et al. Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood. 2020; 135(9): 680–688. doi:10.1182/blood.201900295910.1182/blood.2019002959705948431932839Search in Google Scholar

7. Rovira M, Suárez-Lledó M. Short- and Long-Term Controls After HSCT. In: Carreras E, Du-four C, Mohty M, Kröger N, eds. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. Cham (CH): Springer; 2019: 149–153.10.1007/978-3-030-02278-5_2132091799Search in Google Scholar

8. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia., J Clin Oncol, 2003, vol. 21: 4642–4649.10.1200/JCO.2003.04.03614673054Search in Google Scholar

9. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009; 15(12): 1628–1633. doi:10.1016/j. bbmt.2009.07.00410.1016/j.bbmt.2009.07.004Search in Google Scholar

10. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357. doi:10.1038/sj.leu.240313510.1038/sj.leu.240313514562125Search in Google Scholar

11. Claire L. Green, Kenneth K. Koo, Robert K. Hills, Alan K. Burnett, David C. Linch, and Rosemary E. Gale Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations J Clin Oncol.2010; 28: 2739–274710.1200/JCO.2009.26.250120439648Search in Google Scholar

12. Jentzsch M, Schwind S, Bach E, Stasik S, Thiede C, Platzbecker U. Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia. Cancers (Basel). 2019; 11(11): 1625. Published 2019 Oct 23. doi: 10.3390/cancers11111625Search in Google Scholar

13. Balsat M, Renneville A, Thomas X, et al. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. J Clin Oncol. 2017; 35(2): 185–193. doi:10.1200/JCO.2016.67.187510.1200/JCO.2016.67.187528056203Search in Google Scholar

14. Kayser S, Benner A, Thiede C, et al. Pretrans-plant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Blood Cancer J. 2016; 6(7): e449. Published 2016 Jul 29. doi:10.1038/bcj.2016.46Search in Google Scholar

15. Qin YZ, Wang Y, Xu LP, et al. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol. 2017; 10(1): 44. Published 2017 Feb 6. doi:10.1186/s13045-017-0414-2Search in Google Scholar

16. Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013; 121(20): 4056–4062. doi:10.1182/blood-2012-11-46834810.1182/blood-2012-11-46834823535063Search in Google Scholar

17. Rücker FG, Agrawal M, Corbacioglu A, et al. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood. 2019; 134(19): 1608–1618. doi:10.1182/blood.201900142510.1182/blood.201900142531554635Search in Google Scholar

18. Tang FF, Xu LP, Zhang XH, et al. Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia. Br J Haematol. 2018; 180(3): 448–451. doi:10.1111/bjh.1434010.1111/bjh.1434027650511Search in Google Scholar

19. Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010; 115(2): 198-205. doi:10.1182/blood-2009-04-21253010.1182/blood-2009-04-21253019901261Search in Google Scholar

20. Mannelli F, Ponziani V, Bencini S, et al. CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biologicalfeatures. Haematologica.2017; 102(3): 529–540. doi:10.3324/haematol.2016.15191010.3324/haematol.2016.151910539497528250006Search in Google Scholar

21. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010; 28(16): 2739–2747. doi:10.1200/JCO.2009.26.250110.1200/JCO.2009.26.250120439648Search in Google Scholar

22. Rein LA, Sung AD, Rizzieri DA. New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation. IntJHematolOncol. 2013; 2(1): 10.2217/ijh.13.4. doi:10.2217/ijh.13.410.2217/ijh.13.4384100624303095Search in Google Scholar